Drug Trial Radar · NCT02134834
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595
Last checked: Nov 19, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 2014
Primary completion
Aug 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are to assess the safety, tolerability and pharmacokinetic profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at single escalating doses.
Conditions
- Healthy Volunteers
- Bacterial Infections
Interventions
OP0595Drug
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
PlaceboDrug
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety from baseline through the end of the studyTime frame: Day 1 to Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.